Can you take Acebutolol with Amifostine?

Acebutolol has a major potential interaction with Allergies.

The use of beta-adrenergic receptor blocking agents (aka beta-blockers) in patients with a history of allergic reactions or anaphylaxis may be associated with heightened reactivity to culprit allergens. The frequency and/or severity of attacks may be increased during beta-blocker therapy. In addition, these patients may be refractory to the usual doses of epinephrine used to treat acute hypersensitivity reactions and may require a beta-agonist such as isoproterenol.

Amifostine has a major potential interaction with Arrhythmia.

Patients who are hypotensive or in state of dehydration, or those that are unable to discontinue antihypertensive treatment 24 hours prior to amifostine administration should not receive amifostine. Transient hypotensive episodes have occurred in 62% of patients receiving amifostine. Three percent of patients required discontinuation of amifostine. Therapy with amifostine should be administered cautiously in patients adversely affected by hypotensive effects such as cardiovascular conditions of arrhythmia, angina, or CHF or cerebrovascular conditions of or history of stroke or ischemic attacks. Clinical monitoring of blood pressure is necessary.

Acebutolol has a moderate potential interaction with Asthma.

Patients with bronchospastic disease, should, in general, not receive beta blockers, including cardioselective beta-blockers. Because of the relative beta-1 selectivity, cardioselective beta-blockers may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. Because beta-1 selectivity is not absolute, the lowest possible dose of these agents should be used. Consider administering in smaller doses to avoid the higher plasma levels associated with the longer dosing intervals. If dosage must be increased, dividing the dose should be considered to achieve lower peak blood levels. It is recommended to have bronchodilators, including beta-2 agonists, readily available or administered concomitantly if necessary.

Acebutolol has a major potential interaction with Cardiogenic Shock.

The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with hypotension or cardiogenic shock. Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to further depress cardiac output and blood pressure, which can be detrimental in these patients.

Amifostine has a major potential interaction with Cerebral Vascular Disorder.

Patients who are hypotensive or in state of dehydration, or those that are unable to discontinue antihypertensive treatment 24 hours prior to amifostine administration should not receive amifostine. Transient hypotensive episodes have occurred in 62% of patients receiving amifostine. Three percent of patients required discontinuation of amifostine. Therapy with amifostine should be administered cautiously in patients adversely affected by hypotensive effects such as cardiovascular conditions of arrhythmia, angina, or CHF or cerebrovascular conditions of or history of stroke or ischemic attacks. Clinical monitoring of blood pressure is necessary.

Acebutolol has a moderate potential interaction with Cerebrovascular Insufficiency.

Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse. If signs or symptoms suggesting reduced cerebral blood flow are observed, consideration should be given to discontinuing these agents.

Acebutolol has a moderate potential interaction with COPD.

Patients with bronchospastic disease, should, in general, not receive beta blockers, including cardioselective beta-blockers. Because of the relative beta-1 selectivity, cardioselective beta-blockers may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. Because beta-1 selectivity is not absolute, the lowest possible dose of these agents should be used. Consider administering in smaller doses to avoid the higher plasma levels associated with the longer dosing intervals. If dosage must be increased, dividing the dose should be considered to achieve lower peak blood levels. It is recommended to have bronchodilators, including beta-2 agonists, readily available or administered concomitantly if necessary.

Amifostine has a major potential interaction with Dehydration.

Patients who are hypotensive or in state of dehydration, or those that are unable to discontinue antihypertensive treatment 24 hours prior to amifostine administration should not receive amifostine. Transient hypotensive episodes have occurred in 62% of patients receiving amifostine. Three percent of patients required discontinuation of amifostine. Therapy with amifostine should be administered cautiously in patients adversely affected by hypotensive effects such as cardiovascular conditions of arrhythmia, angina, or CHF or cerebrovascular conditions of or history of stroke or ischemic attacks. Clinical monitoring of blood pressure is necessary.

Amifostine has a major potential interaction with Dehydration.

Patients who are dehydrated should not receive amifostine therapy and appropriate hydration prior to administration of amifostine is necessary. Hypotensive episodes have occurred in 62% of patients receiving amifostine. Amifosine reduces the cumulative renal toxicity associated with cisplatin therapy.

Acebutolol has a major potential interaction with Diabetes Mellitus.

Beta-adrenergic receptor blocking agents (aka beta-blockers) may mask symptoms of hypoglycemia such as tremors, tachycardia and blood pressure changes. In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced hypoglycemia and delaying the recovery of normal blood glucose levels. Since cardioselectivity is not absolute, larger doses of beta-1 selective agents may demonstrate these effects as well. Therapy with beta-blockers should be administered cautiously in patients with diabetes or predisposed to spontaneous hypoglycemia.

Acebutolol has a moderate potential interaction with Glaucoma/Intraocular Hypertension.

Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure. Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or discontinuation of beta-blocker therapy.

Acebutolol has a major potential interaction with Heart Block.

The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present). Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.

Acebutolol has a major potential interaction with Heart Failure.

Beta-adrenergic receptor blocking agents (aka beta-blockers) in general should not be used in patients with overt congestive heart failure (CHF). Sympathetic stimulation may be important in maintaining the hemodynamic function in these patients, thus beta-blockade can worsen the heart failure. However, therapy with beta-blockers may be beneficial and can be administered cautiously in some CHF patients provided they are well compensated and receiving digitalis, diuretics, an ACE inhibitor, and/or nitrates. Carvedilol, specifically, is indicated for use with these agents in the treatment of mild to severe heart failure of ischemic or cardiomyopathic origin. There is also increasing evidence that the addition of a beta-blocker to standard therapy can improve morbidity and mortality in patients with advanced heart failure, although it is uncertain whether effectiveness varies significantly with the different agents. Data from one meta-analysis study suggest a greater reduction of mortality risk for nonselective beta-blockers than for beta-1 selective agents.

Amifostine has a major potential interaction with Heart Failure.

Patients who are hypotensive or in state of dehydration, or those that are unable to discontinue antihypertensive treatment 24 hours prior to amifostine administration should not receive amifostine. Transient hypotensive episodes have occurred in 62% of patients receiving amifostine. Three percent of patients required discontinuation of amifostine. Therapy with amifostine should be administered cautiously in patients adversely affected by hypotensive effects such as cardiovascular conditions of arrhythmia, angina, or CHF or cerebrovascular conditions of or history of stroke or ischemic attacks. Clinical monitoring of blood pressure is necessary.

Acebutolol has a major potential interaction with Hemodialysis.

Acebutolol is moderately removed by hemodialysis and should be administered after dialysis when the patient is hemodynamically stable to avoid marked falls in blood pressure. The hemodynamic status should be closely monitored before and after the dose.

Acebutolol has a moderate potential interaction with High Cholesterol.

Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles. Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers. Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.

Acebutolol has a moderate potential interaction with Hyperthyroidism.

When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm. To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks. Patients should be advised not to discontinue treatment without first consulting with the physician. Close monitoring is recommended during and after therapy withdrawal.

Amifostine has a moderate potential interaction with Hypocalcemia.

Hypocalcemic effects during amifostine therapy are rare, but appear to result from inhibition of parathyroid hormone secretion and bone resorption and from increased urinary calcium elimination. Therapy with amifostine should be administered cautiously in patients with or predisposed to hypocalcemia, including hypoparathyroidism.

Acebutolol has a major potential interaction with Hypotension.

The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with hypotension or cardiogenic shock. Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to further depress cardiac output and blood pressure, which can be detrimental in these patients.

Amifostine has a major potential interaction with Hypotension.

Patients who are hypotensive or in state of dehydration, or those that are unable to discontinue antihypertensive treatment 24 hours prior to amifostine administration should not receive amifostine. Transient hypotensive episodes have occurred in 62% of patients receiving amifostine. Three percent of patients required discontinuation of amifostine. Therapy with amifostine should be administered cautiously in patients adversely affected by hypotensive effects such as cardiovascular conditions of arrhythmia, angina, or CHF or cerebrovascular conditions of or history of stroke or ischemic attacks. Clinical monitoring of blood pressure is necessary.

Acebutolol has a major potential interaction with Ischemic Heart Disease.

Heightened sensitivity to catecholamines may occur after prolonged use of beta-adrenergic receptor blocking agents (aka beta-blockers). Exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following abrupt withdrawal of therapy. Cessation of beta-blocker therapy, whenever necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks in patients with coronary insufficiency. Patients should be advised not to discontinue treatment without first consulting with the physician. In patients who experience an exacerbation of angina following discontinuation of beta-blocker therapy, the medication should generally be reinstituted, at least temporarily, along with other clinically appropriate measures.

Amifostine has a major potential interaction with Ischemic Heart Disease.

Patients who are hypotensive or in state of dehydration, or those that are unable to discontinue antihypertensive treatment 24 hours prior to amifostine administration should not receive amifostine. Transient hypotensive episodes have occurred in 62% of patients receiving amifostine. Three percent of patients required discontinuation of amifostine. Therapy with amifostine should be administered cautiously in patients adversely affected by hypotensive effects such as cardiovascular conditions of arrhythmia, angina, or CHF or cerebrovascular conditions of or history of stroke or ischemic attacks. Clinical monitoring of blood pressure is necessary.

Acebutolol has a moderate potential interaction with Liver Disease.

Acebutolol should be used cautiously in patients with impaired hepatic function.

Acebutolol has a moderate potential interaction with Myasthenia Gravis.

Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness. Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms. Use cautiously in patients with myasthenia gravis.

Acebutolol has a major potential interaction with Peripheral Arterial Disease.

Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease. In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels. Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease. Close monitoring for progression of arterial obstruction is advised.

Acebutolol has a moderate potential interaction with Pheochromocytoma.

Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta receptor-mediated vasodilatation in skeletal muscle. In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent. Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.

Acebutolol has a moderate potential interaction with Psoriasis.

The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.

Acebutolol has a major potential interaction with Renal Dysfunction.

The active metabolite of acebutolol, diacetolol, is eliminated primarily by the kidney. Patients with renal impairment may be at greater risk for adverse effects due to metabolite accumulation. Dosage adjustments are recommended for patients with moderate to severe renal dysfunction (CrCl < 50 mL/min).

Acebutolol has a major potential interaction with Sinus Node Dysfunction.

The use of beta-adrenergic receptor blocking agents (aka beta-blockers) is contraindicated in patients with sinus bradyarrhythmia or heart block greater than the first degree (unless a functioning pacemaker is present). Due to their negative inotropic and chronotropic effects on the heart, the use of beta-blockers is likely to exacerbate these conditions.

Acebutolol has a moderate potential interaction with Tachyarrhythmia.

Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker. In one case, this result was reported after an initial dose of 5 mg propranolol. The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.